France's ANSM raises GMP concerns at Brazilian aseptic plant

By Dan Stanton

- Last updated on GMT

Image: iStock/alexis84
Image: iStock/alexis84

Related tags Gmp

Nova DFL’s dental adrenaline product has been denied marketing authorisation after French regulators raised seven critical deficiencies at its facility in Brazil.

An inspection of the Rio de Janeiro facility in February led to France’s Agence Nationale de Sécurité du Médicament (ANSM) issuing a statement of non-compliance with GMP citing seven critical deficiencies and seven major deficiencies, a version of which is embedded below.

The deficiencies centred on problems with aseptic production, with the first slamming the plant’s quality system and its “poor handling of deviations, poor handling of product quality reviews, and absence of risk management consideration in the quality manual.”

The ANSM also cited unsuitable operator behaviour, saying aseptic workers: “Joined hands, stand by crossed arms, arms touching the body at several occasions, rapid motions, no disinfection of gloves before entering hands in grade A, whole upper part of the body entering into grade A, no dedicated storage of the tool used to grab cartridges, and an operator used his grabbing tool again after it had dropped on the ground.”

The inspection came about after the firm – NOVA DFL industrie et commerce France – applied for marketing approval of its injectable adrenaline solution for dental use, Artiadre 40 mg/mL, with the French regulators last year.

The ANSM marked an inspection of the site as an action point in October, and after raising the deficiencies has refused the application request.

Refusal of the national marketing authorisation request of the product ARTIADRE® 100 40mg/ml 0,01 mg/ml, aseptically prepared sterile product,” ​the ANSM said in its report.

“According to the information provided by the site, no EU customer was identified for any medicinal product manufactured by the site. National competent authorities should evaluate the criticality of products being supplied by this manufacturing site and enact measures to ensure continued supplied where appropriate.”


Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us